RU2813193C1 - Antimicrobial drug in form of colloidal solution, method of obtaining antimicrobial drug in form of colloidal solution (embodiments) - Google Patents

Abstract

FIELD: pharmaceuticals.

SUBSTANCE: antimicrobial drug in the form of a colloidal solution is disclosed, the said drug includes silver proteinate, purified water, glycerine and polyvinylpyrrolidone with a molecular weight of 700,000 to 900,000 g/mol; characterized by an average particle size of colloidal silver from 20 to 32 nm, a size value of 50% of colloidal silver particles from 5 to 20 nm; average value ζ — potential of colloidal silver particles from -0.3 to 0.83 mV, ratio of the following colloidal solution components: 1–5 wt.% of silver proteinate, 5–15 wt.% of glycerol, 0.1–0.5 wt.% of polyvinylpyrrolidone with a molecular weight of 700,000 to 900,000 g/mol, the rest is purified water. The methods of preparing an antimicrobial drug in the form of a colloidal solution are also disclosed.

EFFECT: group of inventions provides an increase in the antimicrobial drug in the form of a colloidal solution storage time after opening, in reducing the size of colloidal silver particles in the composition of an antimicrobial drug in the form of a colloidal solution while maintaining ζ-particle potential.

16 cl, 3 tbl, 6 ex

Description

The claimed technical solution relates to the field of pharmaceuticals, to an antimicrobial drug in the form of a colloidal solution, characterized by the presence of silver proteinate in its composition, which has a long shelf life after opening, which is facilitated by a reduction in the size of colloidal silver particles in its composition while maintaining the ζ-potential of the particles, except Moreover, expanding the arsenal of means to suppress the growth of pathogenic microflora of the human body, to increase the effectiveness of the treatment of infectious and inflammatory diseases, namely acute and chronic rhinitis, external otitis, conjunctivitis, blepharitis and blenorrhea, gonorrheal chronic urethritis. Terms used:

Medicines are medicines in the form of dosage forms used for the prevention, diagnosis, treatment of a disease, rehabilitation, for the preservation, prevention or termination of pregnancy (Federal Law of April 12, 2010 N 61-FZ (as amended on July 14, 2022) “On Treatment medicines").

Dosage form is the state of a medicinal product corresponding to the methods of its administration and use and ensuring the achievement of the required therapeutic effect (Federal Law dated 04/12/2010 N 61-FZ (as amended on 07/14/2022) “On the Circulation of Medicines”).

Colloidal solution - A solution whose particle size ranges from 10 ^-9 to 5×10 ^-7 m (1 - 500 nm). It differs from the true solution (particle size less than 10 ^-9 m), as a rule, it is opaque. There are colloidal solutions of gas in liquid (foam), liquid in liquid (emulsion), solid in liquid (suspension), etc. (Explanatory English-Russian dictionary of nanotechnology. - M. - V. V. Arslanov. 2009).

ζ-potential - electrokinetic potential of a colloidal particle (zeta potential) - potential that determines the charge of a granule of a colloidal particle, representing the difference in the sum of the charges of potential-determining ions and the charges of counterions located in the adsorption layer. Zeta potential is an indicator of the stability of a disperse system (General chemistry: textbook. A.V. Zholnin; ed. V.A. Popkov, A.V. Zholnin. 2012).

Combination - I; Wed 1. to Combine and Combine. S. theory and practice. 2. A connection, an arrangement of something, forming a unity, a whole. (Encyclopedic Dictionary).

Dispersed phase - colloidal particles that are dispersed throughout the dispersion medium (General chemistry: textbook. A.V. Zholnin; ed. V.A. Popkov, A.V. Zholnin. 2012).

Dispersion medium is a continuous part (phase) of a disperse system in which particles of the dispersed phase are distributed (General chemistry: textbook. A.V. Zholnin; ed. V.A. Popkov, A.V. Zholnin. 2012).

Sedimentation stability - the resistance of particles of a dispersed system to sedimentation under the influence of gravity (General chemistry: textbook. A.V. Zholnin; ed. V.A. Popkov, A.V. Zholnin. 2012).

The antibacterial properties of silver proteinate have been known for a long period and are due to the content of colloidal silver particles obtained during the interaction of compounds of silver oxide, silver nitrate or other silver salt with gelatin, serum albumin, casein or peptone (Alphabetical index of drugs RLS, http://www .rlsnet.ru/mnn_index_id_1143.htm).

An aqueous solution of silver proteinate is used for medicinal purposes. However, the drug in this form has a short shelf life in the form of an aqueous solution (2-3 weeks), as a result of which the industrial production of silver proteinate solution is difficult, and for a certain time the drug was produced exclusively in industrial pharmacies.

At the moment, technical solutions are known containing silver proteinate, which are obtained in solid dosage form for preparing a solution of silver proteinate before use.

A technical solution is known in the form of a method for organizing a means for suppressing the growth of pathogenic microflora, a means for suppressing the growth of pathogenic microflora (Application RU 2020121448 A, IPC A61K 9/14 (2006.01), A61K 33/38 (2006.01), A61R 31/04 (2006.01) , priority dated 06/23/2020, published 12/23/2021).

A technical solution is known that describes a composition containing silver proteinate and a method for its production (Patent RU 2675628 C2, IPC A61K 31/00 (2006.01), A61K 33/38 (2006.01), A61K 9/20 (2006.01), A61P 31/04 (2006.01), MPKA61K9/08, priority dated 12/23/2016, published 12/21/2018).

There is a known technical solution aimed at obtaining an aqueous solution of silver proteinate at home, which describes an antibacterial system for suppressing the growth of pathogenic microflora, a composition based on it, a method for organizing a composition based on an antibacterial system for suppressing the growth of pathogenic microflora, the claimed invention (Patent RU 2563238 C1, IPC A61K 31/79 (2006.01), A61K 33/38, priority dated 03/26/2014, published 09/20/2015).

The disadvantage of the known technical solutions is the need for additional manipulations on the part of the patient when preparing an antibacterial solution, consisting in dissolving tablets or powder, which does not quickly provide a therapeutic effect when used, and also increases the risk of preparing a therapeutic solution with a silver concentration that exceeds the permissible and safe for application, or insufficient for effective treatment.

A known technical solution is aimed at stabilizing silver proteinate in the finished aqueous solution by pre-treating it with an electron flow at a given dose. (Patent RU 2646105 C1, IPC A61K 38/17, priority dated 12/28/2016, published 03/01/2018).

A known technical solution is a Bioadhesive antibacterial composition, a method of its manufacture (variants) (Patent RU 2745998 C1, IPC A61K 9/08, A61K 33/38 A61K 47/32, A61K 47/38, A61R 31/04 priority dated 01/17/2020, published 04/05/2021).

The disadvantages of the known technical solutions are that the stability of solutions has been proven when stored in sealed packaging, while when this packaging is opened and exposed to air, the stability of the solution can be significantly reduced, which is often noted in the form of corresponding notes on the packaging of medicinal products.

A known technical solution is the drug Protargol, a solution for topical use of 2%, in which Protargol in an amount of 0.2 g is dissolved in 10 ml of purified (https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b7ef2baf- f9b9-4751-b4b2-99ee62985e1d&t=).

The disadvantages of the known technical solutions are that the shelf life of the drug solution is only 10 days, which makes it necessary to dispose of the solution even if there is a remainder of the solution.

The author was tasked with developing an antimicrobial drug containing silver proteinate as an active principle, which has a longer shelf life after opening.

The problem is solved by the fact that the antimicrobial drug is in the form of a colloidal solution, including silver proteinate, purified water, glycerin and polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol; characterized by an average particle size of colloidal silver from 20 to 32 nm; the size value of 50% of colloidal silver particles is from 5 to 20 nm; the average value of ζ - potential of colloidal silver particles from -0.3 to 1 mV; ratio of colloidal solution components, wt. %:

Silver proteinate 1-5 Glycerol 5-15 Polyvinylpyrrolidone with molecular weighing from 700,000 to 1,000,000 g/mol 0.1-0.5 Purified water Rest

Strong silver proteinate and mild silver proteinate can be used as silver proteinate. Water for injection can be used as purified water. The antimicrobial drug is further characterized by the fact that the colloidal solution is suitable for dispersed dispersion of the dose through a dosing device, including in the form of a spray.

A method for producing an antimicrobial drug in the form of a colloidal solution, including the use of silver proteinate, purified water, glycerin and polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol; preparing a solution by dissolving polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol and glycerol in purified water, introducing silver proteinate into the resulting solution, stirring until dissolved, filtering to obtain a colloidal solution, characterized by an average particle size of colloidal silver from 20 to 32 nm ; while 50% of colloidal silver particles have a size from 5 to 20 nm; the average value of ζ - potential of colloidal silver particles from -0.3 to 1 mV; content of colloidal solution components, wt. %:

Silver proteinate 1-5 Glycerol 5-15 Polyvinylpyrrolidone with molecular weighing from 700,000 to 1,000,000 g/mol 0.1-0.5 Purified water Rest

Strong silver proteinate and mild silver proteinate can be used as silver proteinate. Water for injection can be used as purified water. The antimicrobial medicinal product in the form of a colloidal solution is suitable for packaging in a sealed container designed to be used as a dosing device, including in the form of a spray.

The technical effect of the proposed technical solution is to increase the storage time of the antimicrobial drug in the form of a colloidal solution after opening, to reduce the size of colloidal silver particles in the composition of the antimicrobial drug in the form of a colloidal solution while maintaining the ζ-potential of the particles.

Table 1 presents the results of studying the stability of solution 2 after opening, example 5.

Table 2 presents the results of studying the stability of solution 3 after opening, example 5.

Table 3 presents the results of studying the stability of solution 4 after opening, example 5.

The essence of the proposed technical solution is explained as follows.

For medicinal products, the use of which requires storage after opening, it is legally required to determine the shelf life of the drug after opening and reflect this information on the label (Decision of the Council of the Eurasian Economic Commission dated 03.11.2016 N 88 “On approval of requirements for instructions for the medical use of medicinal products and general characteristics of medicinal products for medical use" (together with the "Requirements for instructions for medical use of a medicinal product and general characteristics of a medicinal product for medical use").

Dosage forms of silver proteinate known today (powders, tablets, solutions) imply storage of the solution for 30 days after preparing the solution of the solid dosage form or opening the finished solution (https://grls.rosminzdrav.ru/grls.aspx?s= %D1%81%D0%B5%D1%80%D0%B5%D0%B1%D1%80%D0%B0%20%D0%BF%D1%80%D0%BE%D1%82%D0%B5 %D0%B8%D0%BD%D0%B0%D1%82&m=mnn).

Given the colloidal structure of the silver proteinate solution, the short-term retention of sedimentation stability is related to the particle size.

In disperse systems, particles settle under the influence of gravity much faster than they are displaced as a result of Brownian motion. Calculations in sedimentation analysis are based on the use of the Stokes equation, which for spherical particles has the form:

Where - volume of a dispersed particle, (ρ-ρ ₀ ) - difference between the density of a dispersed phase particle and the density of a dispersion medium, g - acceleration of free fall, ω - rate of settling (sedimentation) of a particle - speed of movement of a particle, η - viscosity of a dispersion medium, r - radius of the dispersed phase particle.

Then the sedimentation rate can be calculated:

According to equation (2), with an increase in the size (radius) of a particle of the dispersed phase and a decrease in the viscosity of the medium, the sedimentation rate will increase in direct proportion (Mikheeva E.V., Pikula N.P. Physical and colloidal chemistry. / Textbook for full-time and part-time IGND students training. - Tomsk: TPU Publishing House, 2009. - 267 p.).

The authors discovered the ability of a combination of polyvinylpyrrolidone with a molecular weight from 700,000 to 1,000,000 g/mol and glycerol to influence the particle size of silver proteinate upon dissolution. In the claimed technical solution, the medicinal substance is silver proteinate, and the composition of the claimed technical solution includes glycerin and polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol; which, when used together, act as a stabilizer for colloidal silver particles.

The inventive composition of the antimicrobial drug makes it possible to obtain silver proteinate in the form of a colloidal solution, which has greater sedimentation stability due to a decrease in the particle size of colloidal silver, characterized by an average particle size of colloidal silver from 20 to 32 nm; the size value of 50% of colloidal silver particles is from 5 to 20 nm; the average value of the ζ-potential of colloidal silver particles is from -0.3 to 1 mV. In addition, this makes it possible to prepare an antimicrobial drug suitable for precise dosing of a therapeutic solution only to the site of infection, especially to the mucous surface of the tissue, for example, in the form of drops or a spray.

In the first variant of the method for obtaining an antimicrobial drug in the form of a colloidal solution, including silver proteinate, purified water, glycerin and polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol; characterized by an average particle size of colloidal silver from 20 to 32 nm, a size value of 50% of colloidal silver particles from 5 to 20 nm; the average value of the ζ-potential of colloidal silver particles is from - 0.3 to 1 mV, with the ratio of the components of the colloidal solution in wt. % indicated above, the main steps are carried out as follows:

- Polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol is dissolved in purified water;

- Glycerin is added to a solution of polyvinylpyrrolidone with a molecular weight from 700,000 to 1,000,000 g/mol with stirring;

- Silver proteinate is added to a solution of polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol and glycerol with stirring;

- The resulting solution is filtered, obtaining an antimicrobial drug in the form of a colloidal solution suitable for packaging in a sealed vessel, made with the possibility of using a dosing device, including in the form of a spray;

- The antimicrobial drug is packaged in a sealed bottle, designed with the possibility of dispersed dispersion of the dose through a dosing device, including in the form of a spray, or with the possibility of dosing with a pipette, as well as with the possibility of storage at room temperature.

In the second variant of the method for obtaining an antimicrobial drug in the form of a colloidal solution, including silver proteinate, purified water, glycerin and polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol; characterized by an average particle size of colloidal silver from 20 to 32 nm, a size value of 50% of colloidal silver particles from 5 to 20 nm; the average value of the ζ-potential of colloidal silver particles is from -0.3 to 1 mV, with the ratio of the components of the colloidal solution in wt. % indicated above, the main steps are carried out as follows:

- Polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol is dissolved in purified water;

- Add silver protein to the resulting solution to obtain a mixture;

- Dry the resulting mixture;

- Form a solid dosage form from the mixture in the form of a powder, in the form of granules or in the form of tablets;

- Prepare a solution of glycerin in purified water;

- Dissolve the solid dosage form in a solution of glycerin in water;

- The resulting solution is filtered, obtaining an antimicrobial drug in the form of a colloidal solution suitable for packaging in a sealed vessel, made with the possibility of using a dosing device, including in the form of a spray;

- The antimicrobial drug is packaged in a sealed bottle, designed with the possibility of dispersed dispersion of the dose through a dosing device, including in the form of a spray, or with the possibility of dosing with a pipette, as well as with the possibility of storage at room temperature.

The claimed technical solution is characterized by the following examples.

Example 1

To conduct confirmatory studies, samples of the antimicrobial drug of the following compositions were prepared:

Solution 1 was prepared according to the method disclosed in patent RU 2675628: a tablet containing silver proteinate in an amount of 200 mg and polyvinylpyrrolidone with a molar mass of 14000 g/mol in an amount of 20 mg was dissolved in 10 ml of purified water.

Solutions 2-4 were prepared in accordance with the method disclosed in the claimed technical solution.

For solution 2, polyvinylpyrrolidone with a molecular weight of 700,000 g/mol in an amount of 10 mg was dissolved in purified water in an amount of 9390 mg, glycerol in an amount of 500 mg was added to the solution with stirring, stirred, silver proteinate in an amount of 100 mg was added to the solution with stirring, stirred , filtered the resulting solution through a filter with a rating of 0.45 μm.

For solution 3, polyvinylpyrrolidone with a molecular weight of 700,000 g/mol in an amount of 20 mg was dissolved in purified water in an amount of 8780 mg, glycerol in an amount of 1000 mg was added to the solution with stirring, stirred, silver proteinate in an amount of 200 mg was added to the solution with stirring, stirred , filtered the resulting solution through a filter with a rating of 0.45 μm.

For solution 4, polyvinylpyrrolidone with a molecular weight of 700,000 g/mol in an amount of 50 mg was dissolved in purified water in an amount of 7950 mg, glycerol in an amount of 1500 mg was added to the solution with stirring, stirred, silver proteinate in an amount of 500 mg was added to the solution with stirring, stirred , filtered the resulting solution through a filter with a rating of 0.45 μm.

Solution 5 was the drug Protargol, solution for topical use, 2% (batch 7012020, expiration date II.2022).

Example 2

Determination of the particle size of colloidal silver in the composition of an antimicrobial drug was carried out using the method of photon correlation spectroscopy. A Beckman Coulter Delsa Nano C Submicron Particle Analyzer was used for measurements.

Using a microdispenser, the cuvette was filled with a sample solution in an amount of 1 to 1.5 ml. Additionally, one measurement was made of dilute solutions of 50% sample 50% distilled water (to reduce sample absorption). The measurement was carried out three times.

For solution 1, the average diameter of colloidal silver particles lies in the range from 50.2 to 54.8 nm. 50% of colloidal silver particles have a size between 51.1 and 56.1 nm.

For solution 2, the average diameter of colloidal silver particles lies in the range from 21.5 to 27.9 nm. 50% of colloidal silver particles have a size between 7.6 and 10.8 nm.

For solution 3, the average diameter of colloidal silver particles lies in the range from 25.1 to 29.4 nm. 50% of colloidal silver particles have a size between 19.3 and 34.2 nm.

For solution 4, the average diameter of colloidal silver particles lies in the range from 27.8 to 31.6 nm. 50% of colloidal silver particles range in size from 5.3 to 22.7 nm.

For solution 5, the average diameter of colloidal silver particles lies in the range from 49.5 to 52.7 nm. 50% of colloidal silver particles have a size between 52.7 and 56.7 nm.

Example 3

Determination of the ζ-potential of colloidal silver particles in the composition of an antimicrobial drug was carried out using the electrophoretic light scattering method. A Beckman Coulter Delsa Nano C Submicron Particle Analyzer was used for measurements.

Using a microdispenser, a cell intended for measuring the ζ-potential at high concentrations of samples was filled in an amount of 0.6-0.8 ml. Additionally, one measurement was made of diluted solutions: 0.3 ml in 0.7 ml distilled water. The measurements were carried out according to the method for the Delsa Nano C device. The measurements were carried out three times.

For solution 1, the average value of the ζ-potential of colloidal silver particles lies in the range from -0.16 to 0.43 mV.

For solution 2, the average value of the ζ-potential of colloidal silver particles lies in the range from -0.08 to 0.19 mV.

For solution 3, the average value of the ζ-potential of colloidal silver particles lies in the range from 0.14 to 0.83 mV.

For solution 4, the average value of the ζ-potential of colloidal silver particles lies in the range from -0.32 to 0.44 mV.

For solution 5, the average value of the ζ-potential of colloidal silver particles lies in the range from -0.79 to 0.42 mV.

Example 4

To determine the viscosity of the dispersion medium, a solution of the following composition, wt., was prepared. %:

Glycerin - 10

Polyvinylpyrrolidone with molecular weight not

less from 700,000 to 1,000,000 g/mol - 0.2

Purified water – Rest

Separately, as a reference solution, a solution of polyvinylpyrrolidone with a molecular weight of 14000 g/mol was prepared with the following composition, wt. %:

Polyvinylpyrrolidone with molecular weight

14000 g/mol: 0.2

Purified water – Rest

The measurements were performed using a Fungilab Smart L rotational viscometer; measurements were carried out at a temperature of 25°C, which corresponds to the maximum storage temperature of the antimicrobial drug. As a result, the following viscosity values were obtained:

As can be seen from example 4, the viscosity of the dispersion medium of the colloidal solution of the antimicrobial drug increased by 1.3 times, which will slow down the sedimentation rate of colloidal silver particles by 1.3 times.

As a result, the sedimentation rate can be calculated using the following formula, transforming the radius value as 1/2 the diameter value:

Considering that d ₁ in known technical solutions has an average value of 50 nm, and in the claimed technical solution d ₂ - 25 nm, viscosity η ₁ = 18.6 mPa * s, and η ₁ = 14.2 mPa * s, with other Without changing parameters, the values of sedimentation rates will be correlated as:

Substituting the set values, we get:

Those. the sedimentation rate of colloidal silver particles in known technical solutions is 5.2 times higher than in the claimed one, which means the shelf life of the antimicrobial drug should be at least 156 days.

Example 5

The study of the stability of an antimicrobial drug in the form of a colloidal solution after opening was carried out in accordance with the requirements of GPM.1.1.0009.18 “Stability and shelf life of medicinal products” of the State Pharmacopoeia of the Russian Federation, XIV edition. During the study, samples of the antimicrobial drug in the form of a colloidal solution 2, 3, 4, obtained according to example 1 and placed in dark glass vials, sealed with a cap with a pipette with control of the first opening, were stored at a temperature of 15 to 25 ° C, monitoring the dynamics of indicators quality “Description”, “Alkalinity”, “Quantitative determination”, “Protein decomposition products”, “pH”, “Microbiological purity”.

Previously, the samples of the antimicrobial drug were opened, which was monitored by the tearing off of the corresponding ring on the lid with the pipette, then the lid with the pipette was installed in its original place.

The research results for solution 2 are shown in Table 1.

The research results for solution 3 are shown in Table 2.

The research results for solution 4 are shown in Table 3.

According to the results of the study, solutions of the antimicrobial drug in various concentrations are stable for 6 months (180 days), which is significantly longer than known analogues.

Example 6

To confirm the antimicrobial properties, test solutions 2, 3, 4 of the antimicrobial drug in the form of a colloidal solution were used, obtained in accordance with example 1.

The study of antimicrobial action was carried out by the replication method in accordance with the requirements of GPM.1.2.4.0002.18 “Microbiological purity” of the State Pharmacopoeia of the Russian Federation XIV edition, the following were used as nutrient media for strains: medium No. 1; Wednesday No. 2; Wednesday No. 8. Test - microorganism cultures: Escherichia coli ATCC 25922, Salmonella abony IHE 103/39, Staphylococcus aureus 6538-P, Candida albicans 885-653, Aspergillus brasiliensis ATCC 9642.

Legend:

---- complete suppression of the growth of the test culture in experimental dishes.

++- - partial suppression of the growth of the test culture in experimental dishes.

++++ The growth of the test culture in the experimental dishes is identical to the growth in the control dishes.

As can be seen from example 6, the antimicrobial drug provides complete suppression of the growth of strains of pathogenic bacteria, which confirms the presence of antimicrobial properties.

The advantages of the proposed technical solution are:

1) Reducing the particle size of colloidal silver in the composition of an antimicrobial drug while maintaining the value -potential of colloidal silver particles;

2) Increasing the shelf life of an antimicrobial drug after opening;

3) Reducing the irritating effect due to the introduction of glycerin into the composition of the antimicrobial drug;

4) Increasing the retention time of the antimicrobial drug on the surface of the mucous membranes when used due to the introduction of glycerol and polyvinylpyrrolidone with a molecular weight of 700,000 to 1,000,000 g/mol;

5) Ease of execution in industrial production.

Claims (19)

1. Antimicrobial drug in the form of a colloidal solution, including silver proteinate, purified water, glycerin and polyvinylpyrrolidone with a molecular weight of 700,000 to 900,000 g/mol; characterized by an average particle size of colloidal silver from 20 to 32 nm, a size value of 50% of colloidal silver particles from 5 to 20 nm; the average value of the ζ-potential of colloidal silver particles from -0.3 to 0.83 mV, the ratio of the components of the colloidal solution, wt. %: Silver proteinate 1-5 Glycerol 5-15 Polyvinylpyrrolidone with molecular weighing from 700,000 to 900,000 g/mol 0.1-0.5 Purified water Rest 2. The antimicrobial drug according to claim 1 includes strong silver proteinate as a silver proteinate. 3. The antimicrobial drug according to claim 1 includes mild silver proteinate as a silver proteinate. 4. The antimicrobial drug according to claim 1 includes water for injection as purified water. 5. A method for producing an antimicrobial drug in the form of a colloidal solution, including the use of silver proteinate; purified water, glycerin and polyvinylpyrrolidone with a molecular weight from 700,000 to 900,000 g/mol; preparing a solution by dissolving polyvinylpyrrolidone with a molecular weight of 700,000 to 900,000 g/mol and glycerol in purified water, introducing silver proteinate into the resulting solution, stirring until dissolved, filtering to obtain a colloidal solution characterized by an average particle size of colloidal silver from 20 to 32 nm ; the size value of 50% of colloidal silver particles is from 5 to 20 nm; the average value of the ζ-potential of colloidal silver particles from -0.3 to 0.83 mV; content of colloidal solution components, wt. %: Silver proteinate 1-5 Glycerol 5-15 Polyvinylpyrrolidone with molecular weighing from 700,000 to 900,000 g/mol 0.1-0.5 Purified water Rest 6. The method according to claim 5, including the use of strong silver proteinate as a silver proteinate. 7. The method according to claim 5, including the use of soft silver proteinate as a silver proteinate. 8. The method according to claim 5, including the use of purified water for injection as water. 9. The method according to claim 5, characterized in that the medicinal product in the form of a colloidal solution is suitable for packaging in a sealed container configured to use a dosing device, including in the form of a spray. 10. A method for producing an antimicrobial drug in the form of a colloidal solution, including the use of silver proteinate; purified water, glycerin and polyvinylpyrrolidone with a molecular weight from 700,000 to 900,000 g/mol; preparing a solution of polyvinylpyrrolidone in purified water; introducing silver proteinate into the resulting solution to obtain a mixture, drying the resulting mixture; formation of solid dosage form; preparing a solution of glycerin in purified water; dissolution of the solid dosage form in the latter; filtering the resulting solution, obtaining an antimicrobial drug in the form of a colloidal solution, characterized by an average particle size of colloidal silver from 20 to 32 nm; the size value of 50% of colloidal silver particles is from 5 to 20 nm; the average value of the ζ-potential of colloidal silver particles from -0.3 to 0.83 mV; content of colloidal solution components in wt. %: Silver proteinate 1-5 Glycerol 5-15 Polyvinylpyrrolidone with molecular weighing from 700,000 to 900,000 g/mol 0.1-0.5 Purified water Rest 11. The method according to claim 10, including the use of strong silver proteinate as a silver proteinate. 12. The method according to claim 10, including the use of soft silver proteinate as a silver proteinate. 13. The method according to claim 10, including the use of purified water for injection as water. 14. The method according to claim 10, characterized in that the medicinal product in the form of a colloidal solution is suitable for packaging in a sealed container configured to use a dosing device, including in the form of a spray. 15. The method according to claim 10, characterized in that the solid dosage form is made in the form of a powder, in the form of granules or tablets. 16. The method according to claim 10, characterized in that the weight of the solid dosage form is from 44 to 550 mg.